Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by persistent deficits in social communication and restricted, repetitive patterns of behavior, with onset in early childhood. Its etiology is multifactorial, involving genetic, epigenetic, environmental, and immunological factors that interact during critical windows of neurodevelopment [1] [2] . Increasing attention has been paid to the gut-brain axis as a potential mediator between early-life exposures and ASD risk, with the gut microbiome emerging as a key modulator of immune, metabolic, and neurobehavioral processes [3] - [5] .

Among the dietary factors, β-casomorphin7 (BCM7), an opioid peptide released during the digestion of A1 β-casein in cow milk, has been identified as neuroactive and immunomodulatory, capable of influencing gastrointestinal motility, intestinal permeability, and neuroinflammatory pathways [6] - [8] . Elevated serum BCM7 levels have been reported in children with ASD [9] , and experimental studies suggest that BCM7 can alter tight junction integrity in the gut epithelium and blood-brain barrier (BBB) [10] [11] . The European Food Safety Authority has noted the potential health impacts of β-casomorphins, particularly in vulnerable populations [6] . These findings align with broader evidence linking early nutritional exposures to long-term neurodevelopmental outcomes [12] [13] .

The neonatal period is a critical window for gut microbiome establishment and is influenced by the delivery mode, feeding practices, antibiotic exposure, and environmental contacts [14] - [16] . Exclusive formula feeding has been associated with altered microbial colonization patterns and reduced enzymatic capacity to degrade BCM7, potentially accelerating barrier dysfunction and microglial activation [11] [15] . Early antibiotic use—particularly broad-spectrum agents administered in the neonatal period—can disrupt microbial communities, increase intestinal permeability, and impair blood-brain barrier integrity, with downstream effects on neuroimmune signaling [16] [17] . Certain vaccinations, while essential for preventing infectious diseases, represent controlled immune challenges that may transiently elevate pro-inflammatory mediators; in the context of compromised barriers, these could theoretically amplify neuroinflammatory cascades [18] - [20] . Although large epidemiological studies have found no causal link between vaccination and ASD [21] , the interplay between early immune activation, barrier function, and neurodevelopment remains an area of active investigation [22] .

This article proposes a theoretical autism cascade model linking three early-life exposures—exclusive formula feeding, early antibiotic use, and certain vaccinations—to ASD risk through microbiota alterations, barrier dysfunction, and neuroinflammation. The model integrates evidence from microbiology, immunology, and neuroscience to outline a plausible biological pathway from peripheral exposure to central nervous system effects, with the aim of guiding future longitudinal and interventional research.

This study constructs a theoretical autism cascade model by synthesizing the existing literature on early-life exposure, gut microbiota development, barrier integrity, and neuroimmune interactions. The approach follows established frameworks for conceptual model building in biomedical research [1] [2] .

An analysis of the literature identified three primary early life exposures—exclusive formula feeding, early antibiotic use, and certain vaccinations—as potential initiators of the proposed autism cascade. In addition, two secondary perinatal factors depicted in the model, Caesarean delivery and advanced maternal age, and one environmental factor, limited exposure to diverse microbial environments, were noted as modulators of gut microbiota development and neurodevelopmental risk. Each factor is linked to distinct but converging biological effects on gut microbiota, barrier integrity, and neuroimmune activation.

The proposed autism cascade hypothesis integrates dietary peptides, gut microbiome dynamics, barrier permeability, and neuroimmune activation into a unified explanatory model for a subset of autism spectrum disorder (ASD) cases. Our findings suggest that altered β-casomorphin7 (BCM7) metabolism, secondary to microbial dipeptidyl peptidase4 (DPP4) activity, may permit prolonged systemic exposure to bioactive peptides during critical periods of neurodevelopment [11] [12] . Dysbiosis-associated increases in barrier permeability could facilitate the translocation of these peptides, along with pro-inflammatory cytokines, into the central nervous system, thereby priming microglial activation and altering synaptic signaling [13] [14] .

These findings contribute to the growing recognition of the gut-brain axis as a modifiable pathway in early-life neurodevelopment. By linking dietary peptides and microbiome composition to neuroimmune activation, our study aligns with the emerging pediatric guidelines that emphasize early nutritional and microbial health interventions. This perspective underscores the importance of incorporating dietary, microbiome, and immune considerations into the broader framework of developmental pediatrics.

Microbiome studies in ASD consistently report reduced levels of Bifidobacterium and Prevotella, alongside increased abundance of Clostridium, Desulfovibrio, and Bacteroides [28] [29] . These shifts are associated with altered short-chain fatty acid production, increased gut permeability, and neuroimmune activation. Pro-inflammatory taxa such as Sutterella and Ruminococcus have also been implicated in ASD-related dysbiosis.

Recent reviews have further clarified the microbiome-ASD relationship. Lewandowska-Pietruszka et al. (2023) identified consistent microbial shifts in ASD, including increased Firmicutes and Pseudomonadota, and decreased Bacteroidetes, alongside promising results from probiotic and microbiota transfer therapies [29] . Fang et al. (2025) emphasized the role of the microbiota-gut-brain axis in ASD pathogenesis and proposed dietary interventions to restore microbial balance and modulate neuroimmune signaling [28] . These microbial shifts may influence not only gut permeability but also systemic immune tone and CNS signaling. Volpedo et al. (2025) emphasized the multisystem nature of gut-immune-brain interactions, reinforcing the need to consider microbiome status in neurodevelopmental risk modeling [31] .

These findings reinforce the therapeutic relevance of microbiome-targeted strategies in early pediatric care. Building on the gut-brain axis framework, it is also important to consider central immune mechanisms, particularly microglial responses, that may mediate the downstream effects of gastrointestinal events. Beyond peripheral immune activation, microglia, the resident macrophages of the central nervous system, are increasingly being recognized as key mediators that link systemic signals to neurodevelopmental outcomes [13] . In the context of the autism cascade hypothesis, prolonged exposure to bioactive peptides such as BCM7 may bias microglia toward a pro-inflammatory phenotype [14] . This shift promotes the release of cytokines, chemokines, and reactive oxygen species, which can interfere with synaptic pruning and plasticity during critical developmental stages.

While routine childhood vaccinations are broadly safe and not causally linked to ASD [4] [5] , systemic immune activation—including that triggered by infections or immunizations—was modeled as a theoretical input in the neuroimmune cascade. This approach does not imply clinical risk but reflects emerging interest in how immune stimuli may interact with barrier vulnerability during sensitive neurodevelopmental windows [14] [30] [31] .

DPP4 is the principal enzyme responsible for degrading BCM7 [11] . Reduced DPP4 activity—whether due to genetic variation, altered microbiota composition, or inflammation-induced downregulation—could prolong the half-life of BCM7 in circulation [12] . This may heighten microglial exposure to neuroactive peptides, amplify neuroimmune signaling cascades and potentially sustain low-grade neuroinflammation.

The interplay between diminished DPP4 function and microglial reactivity offers a plausible mechanistic bridge between gastrointestinal events and central nervous system changes. This perspective underscores the value of therapeutic strategies aimed at modulating enzymatic activity or microglial activation to mitigate the downstream neurodevelopmental effects.

The timing of immune challenges may be particularly relevant in infants with early-life dysbiosis and delayed BBB maturation. Studies have shown that BBB integrity develops regionally and gradually, with increased permeability during fetal and neonatal stages [30] . In such contexts, systemic immune stimuli may access central compartments more readily, amplifying neuroimmune signaling.

These mechanistic insights further support the exploration of targeted interventions, as discussed in the following section. Our synthesis also highlights opportunities for clinical translation. For pediatricians, this hypothesis points to the value of integrating dietary history, gastrointestinal health assessments, and microbiome profiles into routine risk evaluations of infants with a family history of ASD. While causal relationships require further validation through longitudinal and interventional studies, such low-risk measures could form part of preventive care strategies aimed at modulating neuroimmune responses during critical developmental periods.

Recent global analyses have demonstrated significant differences in autism prevalence in the presence of specific risk factors. For instance, children born to fathers over 50 years of age show a more than twofold increase in autism risk compared to those born to younger fathers [27] . Similarly, prematurity and low birth weight have been statistically linked to elevated prevalence rates [27] . These findings underscore the importance of stratifying early exposures not only by biological plausibility but also by epidemiological weight [26] [27] .

The potential for clinical application warrants systematic investigation, including the refinement of riskstratification tools and early-life intervention protocols. Future research should examine the longitudinal microbiome dynamics in high-risk infants, accounting for diverse dietary exposures and immune biomarkers. Interventional trials focused on tailored nutrition, targeted probiotics, and immunomodulatory strategies may clarify the feasibility and efficacy of disrupting the proposed autism cascade before symptom onset.

In conclusion, this conceptual framework offers a testable, mechanistic account that bridges the molecular pathways and clinical practice. It expands the field’s capacity to identify modifiable early-life factors and could ultimately inform the development of future preventive strategies for pediatric neurodevelopmental disorders.

This work presents a conceptual synthesis rather than original empirical data; as such, the proposed autism cascade hypothesis remains theoretical. The literature integrated into this framework is heterogeneous in terms of design and population characteristics, which may limit the generalizability of the conclusions. Mechanistic links between dietary peptides, microbiome composition, barrier permeability, and microglial activation were inferred from separate lines of evidence rather than demonstrated within a single longitudinal cohort.

Furthermore, much of the evidence is derived from animal models or small human studies, which may not fully capture the complexity of neurodevelopment in diverse pediatric populations. Potential confounding factors such as genetic variability, environmental exposure, and concurrent medical conditions, were not systematically addressed in the reviewed studies. In particular, genetic heterogeneity and unmeasured environmental exposures—such as toxin load, maternal stress, or socioeconomic factors—may independently influence neurodevelopmental trajectories. These variables could confound the proposed cascade model and warrant further investigation in future studies. This model does not imply that routine childhood immunizations increase the risk of autism spectrum disorder, and current public health guidance supports maintaining standard vaccination schedules.

Finally, the absence of standardized measures for β-casomorphin7 (BCM7) metabolism, dipeptidyl peptidase4 (DPP4) activity, and microglial phenotyping in clinical contexts limits the ability to directly translate these concepts into practice. These limitations underscore the need for well-designed, prospective studies that integrate dietary, microbial, immune, and neurodevelopmental assessments over time.

The autism cascade hypothesis provides a clear, mechanistic framework linking dietary peptides, gut microbiome dysregulation, barrier dysfunction, and neuroimmune activation in a subset of autism spectrum disorder (ASD) cases. Situating these pathways within the context of pediatric preventive care underscores the value of incorporating diet-microbiome-immune considerations into early risk assessments, particularly for infants with a family history of ASD.

This hypothesis supports low-risk, potentially protective strategies, from tailored nutrition to microbiome support, while recognizing the need for rigorous longitudinal and interventional research to clarify causality and feasibility. Ultimately, this integrates molecular mechanisms and clinical applications, expanding opportunities to identify and modify early-life risk factors and charting a path toward preventive approaches in pediatric neurodevelopmental disorders.

The author thanks the National Coalition of Independent Scholars (NCIS) for its support in developing this interdisciplinary framework. Portions of the manuscript text were refined for grammar and clarity using Microsoft Copilot and ChatGPT (OpenAI, San Francisco, CA, USA). These tools were not used for data analysis, interpretation, or the generation of original content. All authors reviewed and approved the final text. No funding was received for this study.

Data supporting this commentary are available from the authors upon reasonable request.

↑ = increase; ↓ = decrease. BCM7 = β-casomorphin-7; DPP4 = dipeptidyl peptidase-4; SCFAs = short-chain fatty acids; ROS = reactive oxygen species. All studies contribute mechanistically to the proposed autism cascade model.